Optimer Pharma Beats 50-day MA – Zacks Tale of the Tape
Source: http://www.zacks.com/stock/news/17833/Optimer+Pharma+Beats+50-day+MA+-+Zacks+Tale+of+the+TapePosted on Monday, March 2nd, 2009 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Optimer Pharmaceuticals Inc. (OPTR) jumped 4% on Monday to trade above a short-term level of resistance at $10.51 after the company said it would soon file for marketing approval of its anti-infective drug fidaxomicin with the European Medicines Agency. OPTR is a Zacks#1 Rank (Strong buy) stock.
“OPTR” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Tags for this Post:
European Medicines Agency, Optimer Pharmaceuticals Inc;, Stocks to Watch, USD, Zacks Market Commentaries
European Medicines Agency, Optimer Pharmaceuticals Inc;, Stocks to Watch, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.